---
run_id: halo-evidence-vs-diagnosis-validation-v9-generic-advice-prompted-07
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: generic_advice_prompted
run_number: 7
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 705
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
condition_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
output_file: model-outputs/generic_advice_prompted-07.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 07)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `generic_advice_prompted`, run 7 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 705, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### The Reasoning
You are currently facing a "false positive" crisis. Your lagging indicators (expansion bookings, renewals) are being artificially inflated by sales incentives (bundle pricing) and roadmap promises. Your leading indicators (usage) are being skewed by "vanity usage" from managers who aren't actually using the tool for its intended purpose: accelerating claims resolution.

The core risk is that DraftPath is a "demo-ware" feature—it looks impressive to buyers and managers, but it fails the "last mile" of utility for the front-line adjuster. The evidence in the health-liability segment is a canary in the coal mine: if an adjuster cannot explain a recommendation to a reviewer, the software is a liability, not an asset.

The **Usage Quality Sprint** tracks *that* people are using it, but not *why* or if the output is correct. The **Commercial Cleanroom** tests pricing power, but you cannot price a product that isn't providing durable value. The **Claim File Review** is the only option that investigates the "truth" of the product: whether the AI's output actually matches the professional judgment of a claims expert. If you find that adjusters are manually rewriting 60% of the plans, no amount of "enablement" or "bundling" will prevent a churn wave in 12 months.

### Trade-offs and Sacrifices
By choosing the Claim File Review, you are sacrificing **immediate commercial certainty**. You are telling the CEO and Board that you cannot yet confirm if the recent revenue spike is organic or artificial. You are also giving up the "fast" quantitative data of the Usage Quality Sprint in favor of slower, qualitative manual audits. You are essentially choosing "Product Truth" over "Sales Momentum."

### The Strongest Reason Against This Recommendation
The Claim File Review is the slowest and most labor-intensive of the options. It requires manual effort from already-stressed adjusters and internal reviewers. In a high-pressure environment where the board is looking for "win" narratives to justify next year's budget, recommending a deep-dive audit that might reveal the product is failing its primary users can be perceived as "momentum killing" or overly academic. It risks alienating a Sales team that is currently hitting their numbers.

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the two regional carriers who plan to remove DraftPath are "outliers" (e.g., they have unique legacy tech stacks or atypical workflows) and that the "abandonment" in health-liability is due to a specific, easily fixable UI gap (like a missing "Reasoning" field) rather than a fundamental failure of the AI's logic. If the friction is purely *presentational* and not *functional*, you don't need a file review; you need to test if the market will pay for the fix.
